YU151081A - Process for producing precursors of a new hypotensive and agent, respectively, for inhibiting the aggregation of blood platelets - Google Patents

Process for producing precursors of a new hypotensive and agent, respectively, for inhibiting the aggregation of blood platelets

Info

Publication number
YU151081A
YU151081A YU01510/81A YU151081A YU151081A YU 151081 A YU151081 A YU 151081A YU 01510/81 A YU01510/81 A YU 01510/81A YU 151081 A YU151081 A YU 151081A YU 151081 A YU151081 A YU 151081A
Authority
YU
Yugoslavia
Prior art keywords
aggregation
inhibiting
agent
blood platelets
producing precursors
Prior art date
Application number
YU01510/81A
Inventor
W N Beverung
R A Partyka
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of YU151081A publication Critical patent/YU151081A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
YU01510/81A 1972-02-04 1981-06-15 Process for producing precursors of a new hypotensive and agent, respectively, for inhibiting the aggregation of blood platelets YU151081A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22372372A 1972-02-04 1972-02-04
US29145072A 1972-09-22 1972-09-22

Publications (1)

Publication Number Publication Date
YU151081A true YU151081A (en) 1983-12-31

Family

ID=26918072

Family Applications (2)

Application Number Title Priority Date Filing Date
YU02107/73A YU210773A (en) 1972-02-04 1973-08-03 Process for obtaining imidazoquinazolin-2-one derivatives
YU01510/81A YU151081A (en) 1972-02-04 1981-06-15 Process for producing precursors of a new hypotensive and agent, respectively, for inhibiting the aggregation of blood platelets

Family Applications Before (1)

Application Number Title Priority Date Filing Date
YU02107/73A YU210773A (en) 1972-02-04 1973-08-03 Process for obtaining imidazoquinazolin-2-one derivatives

Country Status (9)

Country Link
JP (1) JPS5623994B2 (en)
AU (1) AU475978B2 (en)
BE (1) BE794964A (en)
CA (1) CA1009652A (en)
DE (1) DE2305575A1 (en)
FR (1) FR2173988B1 (en)
GB (1) GB1418822A (en)
HK (1) HK15581A (en)
YU (2) YU210773A (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE31617E (en) * 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
NL7807507A (en) 1977-07-25 1979-01-29 Hoffmann La Roche TRICYCLICAL CONNECTIONS.
US4146718A (en) * 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
CA1131631A (en) * 1979-06-20 1982-09-14 Madhukar S. Chodnekar Quinazoline derivatives and pharmaceutical preparations
ZW16481A1 (en) * 1980-08-15 1982-03-10 Hoffmann La Roche Novel imidazoquinazoline derivatives
JPS6028979A (en) * 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd Imidazoquinazoline compound
CA2113115A1 (en) * 1991-07-29 1993-02-18 Vlad E. Gregor Quinazoline derivatives as acetylcholinesterase inhibitors
HU219864B (en) 1994-08-09 2001-08-28 Eisai Co., Ltd. Cgmp-pde inhibitory fused pyridazine derivatives and use thereof
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
GB0808968D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808947D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN108676076A (en) 2011-03-01 2018-10-19 辛纳吉制药公司 The method for preparing guanosine cyclic mono-phosphate agonist
JP6499591B2 (en) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase receptor agonists for use in colon lavage
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase receptor agonists in combination with other drugs
RS65632B1 (en) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
JP2022533251A (en) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド Combinations to lower serum phosphate in patients
WO2022199627A1 (en) * 2021-03-23 2022-09-29 National Institute Of Biological Sciences, Beijing Polycyclic compounds and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE760013A (en) * 1969-12-18 1971-06-08 Smith Kline French Lab IMIDAZO AND PYRIMIDO - (2,1-B) QUINAZOLINES, THEIR PREPARATION PROCESSES AND PHARMACEUTICAL COMPOSITIONS CONTAINING

Also Published As

Publication number Publication date
DE2305575A1 (en) 1973-08-09
BE794964A (en) 1973-08-02
FR2173988B1 (en) 1976-10-22
JPS5623994B2 (en) 1981-06-03
YU210773A (en) 1983-02-28
CA1009652A (en) 1977-05-03
DE2305575C2 (en) 1989-01-12
FR2173988A1 (en) 1973-10-12
GB1418822A (en) 1975-12-24
HK15581A (en) 1981-05-01
JPS4886894A (en) 1973-11-15
AU5166873A (en) 1974-08-01
AU475978B2 (en) 1976-09-09

Similar Documents

Publication Publication Date Title
YU151081A (en) Process for producing precursors of a new hypotensive and agent, respectively, for inhibiting the aggregation of blood platelets
YU39521B (en) Process for the manufacture of new 1,2,4-triazole derivatives
ZA727473B (en) New penicillins,their production and their medicinal use
IL50070A0 (en) Process for the production of 1,1,2,3-tetrachloropropene
PH14191A (en) A process of preparing 2,2-methylenediphenols
ZA726315B (en) New polyepoxide-polysiloxane compounds,processes for their manufacture and their use
ZA737408B (en) New heterocyclic compounds,their production and their medicinal use
ZA731504B (en) New bridgehead-heterocyclic compounds,their production and their medicinal use
YU145272A (en) Process for preparing derivatives of phenyl-3-oxadiazol-1,3,4-one-2
HK15378A (en) New penicillin compounds, their production and their medicinal use
HK62577A (en) Basically substituted benzyl-phthalazinone derivatives, acid addition salts thereof and process for the production thereof
ZA73702B (en) New heterocyclic compounds,their production and their medicinal use
IL43495A0 (en) Process for the manufacture of insulin,analogs and derivatives thereof
IL43474A0 (en) Process for the manufacture of insulin,analogs and derivatives thereof
KR780000046B1 (en) Process for the production of new cyclic urea derivatives
ZA724977B (en) New x-ray contrast agents,their application and process for their production
ZA723058B (en) New x-ray contrast agents,their application and process for their production
IL43738A0 (en) A process and a catalyst for the production of 3-halophenol and 3,5-dihalophenol
GB1400485A (en) Process for the manufacture of 8-oxo-5-thia-1-azabicyclo- 4,2,0-oct-2-ene or -3-ene compounds
EG10720A (en) Eburnaminz-type new alkaloids and salts,and a process for the preparation thereof?
ZA738274B (en) Process for the manufacture of 9,10-seco-oestrane derivatives
YU39457B (en) Process for the manufacture of herbicidal 1,2-dialkyl-3,5-diphenylpirazole salts
IL39058A (en) N-picolylalkanoyl-piperazine derivatives,their salts and process for the preparation thereof
ZA728493B (en) New derivatives of 2-mercapto-pyrido(1,2-b)-1,2,4-thiadiazolium salts and process for their production
PH11943A (en) 2,2"-anhydro-1-b-d-arabinofuranosyl-5-fluorocytosine salts and process of preparation